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Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with systemic sclerosis (SSc). Although a
large proportion of SSc patients have only limited interstitial involvement with an indolent course, in a significant minority ILD is
progressive, requiring prompt treatment and careful monitoring. One of the main challenges for the clinician treating this highly
variable disease is the early identification of patients at risk of progressive ILD, while avoiding potentially toxic treatments in those
whose disease is inherently stable. Easily available and repeatable biomarkers that allow estimation of the risk of ILD progression
and early response to treatment are highly desirable. In this paper, we review the evidence for circulating biomarkers with potential
roles in diagnosis, monitoring of disease activity, or determining prognosis. Peripheral blood biomarkers oﬀer the advantages of
being readily obtained, non-invasive, and serially monitored. Several possible candidates have emerged from studies performed
so far, including SP-D, KL-6, and CCL18. Presently however, there are few prospective studies evaluating the predictive ability of
prospective biomarkers after adjustment for disease severity. Future carefully designed, prospective studies of well characterised
patients with ILD, with optimal definition of disease severity and outcome measures are needed.
1. Introduction
Systemic sclerosis (SSc) is a multisystem, autoimmune con-
nective tissue disease, characterised by excessive extracellular
matrix deposition, with remarkable heterogeneity in organ
involvement pattern and prognosis. Pulmonary involvement,
due to pulmonary fibrosis or pulmonary hypertension, is
the leading cause of mortality [1, 2]. The pathogenesis of
pulmonary fibrosis in SSc involves a complex combination
of epithelial and endothelial cell injury with inflammatory
and immune activation. Occurring in response to unknown
initiating factors, the interaction between vascular, epithelial,
and immune dysfunction leads to dysregulated fibroblast
activation and increased extracellular matrix production [3].
This paper will focus on the circulating biomarkers for SSc-
associated interstitial lung disease (SSc-ILD), as summarised
in Figure 1.
A degree of interstitial involvement is present in the
majority of patients with SSc, although severity of lung dis-
ease at presentation and subsequent longitudinal behaviour
are highly variable. In view of the marked variability in
the natural history of SSc-ILD, markers of the likelihood
of ILD progression are needed in clinical management.
Patients with a recent diagnosis of SSc are more at risk
of ILD progression, as the rate of forced vital capacity
(FVC) decline is highest during the first five years since
diagnosis [4]. The severity of ILD also has clear prognostic
implications. Decreased FVC and diﬀusing capacity of the
lung for carbon monoxide (DLCO) have been repeatedly
identified as risk factors for progression, as has the extent
of ILD on CT [5–7]. Recently, Goh et al. have proposed a
simple staging system which subgroups SSc-ILD into limited
and extensive, based on rapid estimation of CT extent,
integrated, if necessary, by FVC levels. This has been found
to be more accurate prognostically than either CT or FVC in
isolation [8] and can be easily applied in the clinical setting
to provide rapid estimation of likelihood of ILD progression.
By contrast, bronchoalveolar lavage (BAL) findings provide
only limited prognostic information and are not linked
to long-term survival or the rapidity of progression of
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Figure 1: Potential biomarkers in SSc-ILD.
lung disease [9, 10], although may provide insights into
pathogenetic mechanisms. Histological pattern is also not
linked to likelihood of disease progression. In contrast to the
idiopathic setting, a pattern of usual interstitial pneumonitis
(UIP), seen only in a minority of patients, is not associated
with a significantly worse survival than the nonspecific
pneumonitis (NSIP) pattern, by far the most common [11].
Contrary to previous perceptions, ILD is found almost as
frequently in limited compared to diﬀuse skin disease, and
the rate of FVC decline does not appear to diﬀer between the
two subsets [12].
ILD in the context of SSc can be asymptomatic and
patients may first present with extensive lung disease. On
the other hand, most patients with SSc have limited ILD
involvement, which will have a stable course even without
treatment. The reliable detection of patients at risk of
lung disease progression is particularly diﬃcult in patients
with mild, early disease. The identification of non-invasive,
prognostic biomarkers that predict the likelihood of disease
progression has the potential to allow timely immunosup-
pressant therapy, while avoiding unnecessary treatment in
patients likely to follow an indolent course. Furthermore,
identification of patients more at risk of disease progression
is needed for cohort enrichment in randomised controlled
clinical trials, which have so far included a proportion of
patients with stable SSc-ILD, thus potentially diluting the
eﬀects of the intervention [13].
Awareness of potential confounding factors is crucial
to correctly interpret biomarker associations with SSc-ILD.
In the context of SSc, serum biomarkers can reflect extra-
pulmonary disease activity, including rapidly progressive
diﬀuse skin fibrosis and active systemic disease. From the
pulmonary aspect, DLCO is a sensitive marker of ILD, but
also reflects pulmonary vasculopathy. Indeed, a dispropor-
tionate reduction in DLCO in relation to lung volumes
should prompt the assessment of pulmonary hypertension
[14]. Adjustment for these factors in multivariate analysis
is crucial to assess the correlation between the putative
biomarkers and SSc-ILD.
Biomarkers can fulfil a number of roles, including
identification of pathways involved in disease pathogenesis,
assessment of disease severity, prediction of future disease
behaviour and use as surrogate outcome measures [15]. This
paper focuses on peripheral blood biomarkers, as they oﬀer
a number of advantages—they are readily obtained, can be
measured longitudinally, and thus have the potential to be
integrated into clinical use.
2. Autoantibody Subsets
Autoantibody subsets have strong associations with diﬀerent
patterns of pulmonary involvement. Anti-topoisomerase I
antibodies (ATA), have been consistently associated with
pulmonary fibrosis, while anti-centromere antibodies (ACA)
are linked to pulmonary hypertension and are rarely present
in SSc-ILD [16]. While it is clear that ATA positivity is
associated with a greater risk of lung fibrosis, it remains
unclear whether it is associated with more progressive ILD.
A reduced incidence of lung fibrosis is found in anti-
RNA polymerase III positive patients [17]. The nucleolar
autoantibodies, anti-U3 RNP antibody and anti TH/To,
are linked to an increased risk of pulmonary disease and
appear to be associated with development of pulmonary
hypertension disproportionate to the degree of interstitial
involvement [18].
3. Alveolar Epithelial Proteins
Although the sequence of events in the pathogenesis
of SSc-ILD is not fully understood, ultrastructural stud-
ies have shown that both epithelial and endothelial cell
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injury may precede inflammation and fibrosis [19]. The
increased clearance of technetium-labeled diethylene tri-
amine pentaacetate (99mTc-DTPA) aerosol from the lungs
of patients with SSc-ILD is indicative of a breached epithe-
lial barrier and is associated with more rapid decline
in FVC [20, 21], independently of disease severity. Lung
epithelium-specific proteins leaking into the circulation may
thus represent potential biomarkers of alveolar epithelial
damage.
3.1. Surfactant Proteins (SP-A and SP-D). Secreted by type
II alveolar epithelial cells and airway Clara cells, pul-
monary surfactants are lipoprotein complexes that include
the hydrophobic proteins SP-B and SP-C and hydrophilic
proteins SP-A and SP-D [22]. In addition to stabilising
alveolar surface tension, they play an important role in the
lung’s host defence system, a role mediated primarily by SP-
A and SP-D.
Serum levels of SP-A and SP-D are significantly higher in
SSc patients with pulmonary fibrosis than in those without
[23, 24], and SP-D serum levels are negatively correlated
with VC and DLCO [24, 25]. SP-D levels are more sensitive
than SP-A in detecting ILD as defined by CT. Using cut-oﬀ
levels set at 43.8 ng/mL for SP-A and 110 ng/mL for SP-D, the
sensitivities and specificities for detecting CT-positive ILD
in 42 patients with SSc were 33% and 100% for SP-A and
77% and 83% for SP-D, respectively [23]. Receiver operator
curve analysis demonstrated good sensitivity (89.4%) and
specificity (80%) of SP-D levels >90 ng/mL in the assessment
of “alveolitis” as defined by BAL neutrophilia and/or HRCT
ground glass in the Scleroderma Lung Study [26]. In a small
but prospective study of 35 patients with SSc-ILD followed
over 1–10 years, SP-D levels were seen to definitely increase
over time in 9 out of the 10 patients with worsening ILD,
as defined by changes in symptoms, lung function, and
imaging, compared to mild increases in only 3 out of 25
patients with stable or improving SSc-ILD [24]. In a small,
retrospective study of 6 patients with SSc-ILD by Yanaba et
al., serum SP-D levels were analysed over a mean follow-
up period of 2.3 years. In 3 out of the 4 patients treated
with immunosuppressive therapy, longitudinal SP-D levels
decreased/stabilised in parallel with lung function findings
[25].
3.2. Krebs Von Den Lungen 6 (KL-6). KL-6 is a high-mo-
lecular-weight mucin-like glycoprotein, strongly expressed
by type II alveolar epithelial cells and bronchiolar epithelial
cells [27], which increases following cellular injury and/or
regeneration. Additionally, KL-6 has been shown to have
profibrotic and antiapoptotic eﬀects on lung fibroblasts and
thus may have a role in the pathogenesis of SSc-ILD [28].
Serum KL-6 is elevated in a variety of diﬀerent ILDs,
including the idiopathic interstitial pneumonias, hypersensi-
tivity pneumonitis, drug-induced pneumonitis, sarcoidosis,
and connective tissue disease-associated ILD (CTD-ILD),
reflecting the prominent role of alveolar epithelial injury
and proliferation across ILDs [29]. Serum levels of KL-
6 are significantly higher in SSc patients with pulmonary
fibrosis than in SSc alone, and levels inversely correlate
with VC and DLCO [25, 30]. A threshold of 500U/mL,
commonly used also in the context of other interstitial lung
diseases, provided a 78.8% sensitivity and 90% specificity
in detecting “alveolitis” as defined in the Scleroderma Lung
Study [26]. In a study of 240 patients with a variety of
CTDs, a serum level >500U/mL was a marker of ILD
(sensitivity 0.79; specificity 0.93; diagnostic accuracy 0.896),
and a level >1000U/mL was a marker of “active” progressive
ILD (sensitivity 0.867; specificity 0.865; diagnostic accuracy
0.866), although this was loosely defined as disease requiring
newly added intervention [31]. Bonella et al. found a
stronger correlation for KL-6 than SP-D with HRCT fibrosis
scores and confirmed the described association with FVC and
DLCO [32].
In a retrospective longitudinal study, KL-6 levels were
determined in 39 patients with SSc during a follow-up period
of 0.3–6.1 years [33]. New onset or deterioration of ILD
occurred in 4 patients and was associated with a rapid
increase in serum KL-6 levels. Reflecting its potential use in
serial monitoring of disease activity, levels of KL-6 have been
shown to decrease after treatment with cyclophosphamide
[34]. Satoh et al. evaluated the prognostic significance of
serum KL-6 levels in 219 patients with ILD, including 67
with CTD-ILD. Higher levels of KL-6 were seen in patients
who died during the follow-up period, with a threshold level
of 1000U/mL discriminating nonsurvivors from survivors
[35].
Overall, KL-6 appears to be a promising multipurpose
biomarker that appears to reflect response to treatment and
prognosis in SSc-ILD. Although integrated into clinical prac-
tice in Japan for a number of years, it still requires validation
in a large number of patients with SSc-ILD, particularly
to assess whether it can predict outcome independently of
markers of ILD severity.
4. CC and CXC Chemokines
Chemokines traﬃc leucocytes to sites of inflammation and
are classified into subsets based on the position of their first
two cysteine residues: CC and CXC chemokines. Both bind
to receptors expressed on the surface of leucocytes, CXCR
and CCR, antagonists of which may represent candidates for
targeted therapy.
4.1. CC Chemokine Ligand 18 (CCL18). CCL18, previously
known as pulmonary and activation-regulated chemokine
(PARC), is constitutively expressed at high levels in the
lungs, mainly by alveolar macrophages, and acts as a
chemoattractant for a variety of mononuclear cells. CCL18
production by alveolar macrophages, alternatively activated
by Th2 cytokines, is increased in a number of fibrotic lung
diseases, including SSc-ILD, and correlates with serum levels
[36]. CCL18 has been shown to stimulate fibroblast collagen
synthesis [37], which in turn appears to further increase
CCL18 production [38].
In SSc, serum CCL18 levels are inversely correlated
with baseline lung function and have been associated with
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longitudinal changes in VC and DLCO [36, 39]. In a
longitudinal analysis of 21 patients with SSc-ILD by Kodera
et al., serumCCL18 correlated with ILD activity (determined
by HRCT, lung function, and BAL analysis), possibly more
tightly than KL-6 or SP-D. In a recent, prospective cohort
study of 83 SSc patients over a four-year period by Tiev et al.,
increased serum CCL18 levels were independently predictive
of ILD worsening [40]. A baseline CCL18 level >187 ng/mL
was the best cut-oﬀ (53% sensitivity; 96% specificity)
for identifying subsequent lung function worsening (10%
decrease from baseline of TLC or FVC) or death, with a
hazard ratio of 5.36 (95% CI 2.44–11.75; P = 0.001),
even after adjustment for baseline DLCO and duration of
disease [40]. To our knowledge this is the first large study to
prospectively evaluate the prognostic ability of a biomarker
in SSc-ILD, adjusting for ILD severity and other covariates.
Interestingly, CCL18 has also been prospectively evaluated in
patients with idiopathic pulmonary fibrosis by Prasse et al.
and was found to predict early lung function decline and
mortality, with a similar cut-oﬀ level of 150 ng/mL, again
independently of disease severity [41], suggesting its utility
as a marker of ILD progression independently of the setting.
Overall, if confirmed by separate prospective studies, these
results suggest that serum CCL18 could be used in clinical
management as a marker of progressive ILD, to aid in
targeting treatment to the correct patients, and should be
evaluated as a potential therapeutic target.
4.2. CC Chemokine Ligand 2 (CCL2). CCL2, also known as
monocyte chemoattractant protein-1 (MCP-1), is chemoat-
tractant for monocytes and T cells and has been shown to
induce Th2 cell polarisation, thereby stimulating collagen
production and myofibroblast diﬀerentiation in fibroblasts
[42, 43]. Serum levels are upregulated in SSc and correlate
with the presence of ILD [44–46]. In a study of 33 SSc
patients, serum CCL2 variation correlated with changes in
VC during a 3-year follow-up period [47], although the
number of patients with declining lung function was small.
Bronchoalveolar lavage CCL2 concentration was associated
with the presence of ILD in 32 SSc patients and correlated
with lung function parameters and CT scores [48].
4.3. CXC Chemokine Ligand 10 (CXCL10). CXCL10 displays
strong chemoattractant activity for Th1 lymphocytes with
elevated serum levels seen in various autoimmune diseases
[49]. In SSc, serum levels are significantly increased in the
presence of ILD compared to those without and normal con-
trols [46, 50]. However, a recent retrospective, longitudinal
study of 31 SSc patients found that levels did not correlate
with change in lung function over time [47].
4.4. CXC Chemokine Ligand 12 (CXCL12). The expression
of CXCL12 and its receptor CXCR4 is critical for the
recruitment of circulating progenitor cells during tissue
repair. Circulating CXCR4+ progenitor cells have been
observed to correlate with skin and lung involvement [51]
and are found in the lung tissue of patients with SSc-ILD
but not in controls, with parallel upregulation of its ligand
CXCL12, expressed by alveolar epithelial cells and alveolar
macrophages [52].
5. Leukocytes
5.1. T-Cell Subsets. Two functional subsets of T cells with
distinct cytokine-secretion profiles are well recognised [53].
Type 1 (Th1) T cells predominantly produce interleukin-2
(IL-2) and interferon-gamma (IFN-γ), whereas type 2 (Th2)
T cells produce interleukins IL-4, IL-5, IL-6, IL-10, and IL-13
[54]. These subsets appear to exert opposing roles in tissue
remodelling and fibrogenesis; IFN-γ suppresses fibroblast
activity whereas the Th2 cytokines such as IL-4, IL-6, and
IL-13 are profibrotic either by directly stimulating collagen
synthesis by fibroblasts or indirectly by inducing profibrotic
cytokines such as transforming growth factor-beta (TGF-β)
and connective tissue growth factor (CTGF) [55].
In patients with SSc, a predominant Th2 cytokine profile
has been reported in lung tissue [56], bronchoalveolar lavage
fluid [57], and peripheral blood [56]. In SSc-ILD, a further
marked reduction in the Th1/Th2 ratio compared to SSc
patients without ILD has been reported, with a strong linear
correlation between a lower Th1/Th2 ratio and lower FVC
levels [56]. Serum levels of IL-10 and IL-6 have been found to
be elevated in patients with SSc-ILD compared to SSc alone
[47, 58], and our group has recently shown that elevated IL-
6 is independently associated with lung function worsening
and increased mortality in patients with SSc-ILD (submitted
for publication). Serum levels of IL-15, a pleiotropic cytokine
which may have a pathogenetic role in both fibrotic and
vascular lung disease, were found to strongly correlate with
impaired lung function in SSc [59].
Th17 lymphocytes, recently described as a subset which
synthesise an array of cytokines including IL-17A, are the
main producers of TGF-β among Th subsets [60]. Increased
Th17 cells and IL-17A levels have been detected in the
sera, skin, and lungs of patients with SSc [61–63], although
another study reported normal serum IL-17A levels in SSc
[64]. Th17 is induced by various cytokines including IL-23,
IL-6, and TGF-β; interestingly, IL-23 has also been associated
with the presence of ILD in SSc [65]. IL-22 is a cytokine
which plays a role in the maintenance and integrity of
epithelial barrier function [66], produced by Th17 and Th22
lymphocytes, another novel T-cell subset [67]. Circulating
IL-22- and IL-17-producing T cells were increased in SSc
individuals presenting with ILD, as detected by HRCT and
decreased TLC, compared with those without ILD [68].
5.2. B Cells. B-cell infiltration has been recently demon-
strated in SSc lung and skin [69, 70]. There is evidence of
circulating B cell activation in SSc [71] with overexpression
of CD19, a positive regulator that increases B-cell signals
in response to antigens [72]. In patients with SSc-ILD, B-
cell-depleting therapy with Rituximab significantly improved
lung function in a small, randomised, controlled study
by Daoussis et al. [73], suggesting a crucial role of B-
cells in the progression of fibrosis in SSc. These results
suggest circulating B-cell markers should be assessed in
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relation to lung involvement, as they may ultimately identify
subsets more likely to respond to B-cell depletion treatment
strategies.
6. Macrophages/Monocytes
Macrophages, mostly derived from CD14+ monocytes,
can display two distinct phenotypes of activation: Th1 or
“classically” activated (M1) macrophages arise in response
to IFN-γ or IL-1 whereas Th2, or “alternatively” activated
(M2), macrophages are derived following exposure to Th2
cytokines, including IL-4, IL-13, and IL-10 [74], and are
characterised by an anti-inflammatory and profibrotic phe-
notype. The CD14+ monocyte fraction from peripheral
blood in patients with SSc-ILD is characterised by substan-
tially increased expression of the activation marker CD163,
which colocalises with the M2 marker CD204 [75], and,
following stimulation with lipopolysaccharide, release of the
profibrotic mediators CCL18 and IL-10 [76], characteristic
products of M2 macrophages. There also exists a population
of CD14+/CD45+/collagen I-producing circulating mono-
cytes which are increased in the peripheral circulation of
patients with SSc-ILD compared to controls [76].
7. Matrix Metalloproteinases/Tissue
Inhibitors of Metalloproteinases
Remodelling of the extracellular matrix and maintenance
of basement membrane integrity involve a balance between
the matrix metalloproteinases (MMPs) and their inhibitors,
tissue inhibitors of metalloproteinases (TIMPs). MMP-7
(matrilysin), a metalloproteinase which targets a broad range
of extracellular matrix proteins, was originally found to be
highly overexpressed in IPF lungs [77] and subsequently
in other interstitial lung diseases [78]. In IPF, both BAL
and serum MMP-7 are negatively correlated with FVC
and DLCO [79]. Among SSc patients, higher levels of
serum MMP-7 were seen in patients with lung fibrosis
compared to those without and were associated with lower
DLCO levels, although the association of MMP-7 levels with
ILD progression was not evaluated [80]. Notably, patients
with lung fibrosis and concomitant pulmonary hyperten-
sion had higher mean MMP-7 serum levels compared to
those with lung fibrosis alone, indicative of the potential
confounding issue of underlying vasculopathy in DLCO
reduction.
MMP-9 (gelatinase B), associated with chronic inflam-
matory autoimmune diseases and conditions characterised
by excessive fibrosis, was significantly increased in serum
of SSc patients compared to healthy controls [81] and in
bronchoalveolar lavage of SSc-ILD patients [82]. Interest-
ingly, circulating levels of MMP-12 have been reported to
be tightly inversely correlated with FVC (r = −0.82), and
MMP-12 staining to be significantly increased in SSc-ILD
lungs compared to normal controls [83]. TIMP-1 levels have
been shown to correlate with the presence of ILD in SSc and
to negatively correlate with DLCO, albeit weakly (r = −0.28)
[84].
8. Neutrophil Elastase
Polymorphonuclear neutrophilic leukocyte (PMN) elastase
is a serine proteinase that is believed to modulate extracellu-
lar matrix formation and remodelling following lung injury
[85]. As elegantly reviewed by Hant and Silver, serum levels
of PMN elastase have been reported as significantly increased
in SSc-ILD and interestingly correlated well with SP-D and
KL-6 [15, 86].
9. Profibrotic Growth Factors
Serum connective tissue growth factor (CTGF) has been
found to be increased in SSc patients, and to correlate with
skin and lung fibrosis [87, 88], although longitudinal studies
to evaluate prognostic ability have not been performed.
Interestingly, serum TGF-β, considered one of the master
regulators of tissue fibrosis, is not consistently upregulated
in SSc patients and indeed was found to be reduced in
patients with active diﬀuse skin disease, perhaps reflecting
sequestration to active SSc skin disease [89].
10. Markers of Oxidative Stress
Oxidative stress mediated by free oxygen radicals is believed
to play a role in the pathogenesis of lung fibrosis and of
systemic sclerosis. Serum total antioxidant power, a measure
of global antioxidant activity, was found to be increased in
SSc patients, although did not diﬀer according to presence of
ILD [90]. By contrast, serum isoprostane, a marker of lipid
peroxidation, was associated with SSc-ILD and was inversely
correlated with FVC and DLCO (r = −0.4 for both) [91].
Urinary levels of F2-isoprostanes, generated by free radical
peroxidation of arachidonic acid, also inversely correlated
with DLCO (r = −0.44). Although the association with ILD
severity is interesting, none of the oxidative stress markers
were assessed as potential predictors of ILD progression.
11. Acute-Phase Proteins
Acute-phase reactant proteins are elevated in a proportion
of patients with SSc. An elevated erythrocyte sedimentation
rate (ESR) has been shown to be independently associated
with mortality in a number of studies [92, 93]. C-reactive
protein (CRP) significantly correlates with ESR [94] and
with serum IL-6 in SSc [95]. In 1043 SSc patients, CRP was
observed to correlate with disease severity, poor pulmonary
function, and shorter survival [94]. Sharing a C-terminal
pentraxin domain with CRP, pentraxin 3 (PTX3), an acute-
phase protein produced at disease sites by a number of cell
types, including fibroblasts [96], was found to correlate with
lung function impairment in SSc [97].
12. Vitamin D
Insuﬃcient levels of vitamin D have been reported in a
number of autoimmune diseases [98], including SSc [99].
In a study of 327 patients with SSc, vitamin D deficiency
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was associated with reduced DLCO (P < 0.02) [100]. An
association with DLCO and/or increased pulmonary artery
pressures on echocardiography had also been reported in
two smaller earlier studies [99, 101], suggesting a possible
correlation with pulmonary vasculopathy, rather than ILD.
13. Endothelial Cell Activation
Ultrastructural studies have shown that both epithelial and
endothelial cell injury precede inflammation and fibrosis
[19]. Following endothelial activation, a procoagulant and
profibrotic environment ensues. Endothelin-1 (ET-1), an
endothelial cell product with well-known vasoconstrictor
properties, has also been shown to promote profibrotic
processes, including the induction of myofibroblast diﬀeren-
tiation, contraction, and extracellular matrix synthesis [102].
Increased ET-1 levels have been found in BAL fluid and
lung tissue from patients with SSc [103, 104]. Increased
serum levels of soluble vascular cell adhesion molecule-
1 (sVCAM-1), soluble E-selectin (sE-selectin), vascular
endothelial growth factor (VEGF), and endothelin-1 (ET-
1) have been described in patients with SSc, and have
been variably correlated with internal organ involvement,
including pulmonary fibrosis [105–107]. Anti-endothelial
cell antibodies (AECA), postulated to play a role in vascular
injury in a number of autoimmune diseases, have been
reported in 22%–86% of patients with SSc, depending on
detectionmethods used [108], and have been associated with
a higher frequency of pulmonary fibrosis [109].
14. Serum Biomarkers of Pulmonary
Hypertension in SSc-ILD
A detailed analysis of pulmonary hypertension markers
in SSc is outside of the scope of this paper. Pulmonary
hypertension in SSc (SSc-PH) can occur in the absence of
interstitial lung involvement, in association with ILD and/or
as a consequence of left-sided heart disease. Compared to
patients with SSc-PH alone, those with SSc-ILD associated
PH have a worse prognosis, with a recently reported 3-
year survival of 71% versus 47%, respectively (P = 0.07)
[110]. Indicators suggestive of the development of PH in
the context of ILD include a disproportionate reduction
in DLCO compared to lung volumes and development of
hypoxia [111, 112]. Echocardiography is used as a screening
tool, but in patients with ILD is plagued by low speci-
ficity [113]. Although a right-sided cardiac catheterisation
remains the gold standard for the diagnosis of PH, the
procedure is invasive and cannot be used routinely for
screening/monitoring purposes.
Among serum biomarkers, natriuretic peptides, includ-
ing brain natriuretic peptide (BNP) and N-terminal
pro-brain natriuretic peptide (NT-pro-BNP), released in
response to ventricular stretch by cardiomyocytes, have been
established as informative markers of RV dysfunction in
PH [114, 115]. BNP was found to be a marker of poor
prognosis in patients with chronic lung diseases [116]. In a
study of 90 ILD patients by Corte et al., including 18 with
CTD-ILD, serum BNP correlated with echocardiographic
estimates of pulmonary pressures. Furthermore, a serum
BNP ≥20 pmol·L−1 was associated with a 14-fold increased
mortality compared to patients with BNP <4 pmol·L−1
[117]. However, natriuretic peptide levels only rise when
there is strain to the right ventricle, andmarkers of the earlier
stages of pulmonary vasculopathy are needed to allow early
intervention.
15. Conclusion
The majority of the studies performed to date have identified
a link between serum proteins and the presence or severity
of ILD in the context of SSc. In a disease with extremely
variable presentation and outcome, there is an unmet clinical
need for biomarkers predictive of ILD progression over time,
independently of disease severity. In particular, clinicians
need a biomarker to target patients with early and limited
ILD at higher risk of disease progression for early therapy, so
as to prevent the development of extensive disease. Ideally, a
biomarker would also provide early assessment of response
to treatment and could theoretically identify subsets of
SSc-ILD with diﬀerential response to targeted therapies.
In providing information on the likelihood of future ILD
progression, biomarkers should also allow better selection
of SSc-ILD patients for clinical trials, to enrich trial cohorts
with patients more at risk of disease progression.
To date, there have been very few studies evaluating
the ability of biomarkers to predict SSc-ILD progression.
The most promising biomarkers thus far appear to be
KL-6 and CCL18, and the evidence for their utilisation
in predicting likelihood of progression of SSc-ILD and
monitoring treatment response is encouraging. However, the
panel of investigated biomarkers so far has been limited.
In idiopathic pulmonary fibrosis, prospective, multicentre,
longitudinal trials are underway to identify if a broad array
of biological biomarkers collected at the time of diagnosis
and at various longitudinal time points can be used to
predict the disease course—COMET: correlating outcomes
with biochemical markers to estimate time-progression in
IPF (NCT01071707) and PROFILE: prospective observation
of fibrosis in the lung clinical endpoints (NCT01110694). A
similar endeavour is yet to be undertaken in SSc-ILD.
Prospective, well-designed studies, with detailed charac-
terisation of ILD at baseline, to allow adjustment for disease
severity and meticulous monitoring of disease progression
outcomes and serum biomarkers are needed. The use of high
throughput gene expression, protein and immune serum
biomarker profiling is likely to identify a combination of
biomarkers, each expressing diﬀerent pathogenetic pathways,
that when combined may provide a powerful indication of
the likelihood of ILD progression and allow early evaluation
of response to treatment.
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